Susan Galbraith, AstraZeneca EVP of oncology R&D (Rachel Kiki for Endpoints News)

As­traZeneca's Lyn­parza-Imfinzi com­bo clears PhI­II tri­al in ovar­i­an can­cer

As­traZeneca tout­ed pos­i­tive da­ta for its Lyn­parza-Imfinzi block­buster com­bo to­day with a high-lev­el analy­sis from its DUO-O Phase III tri­al, in new­ly di­ag­nosed pa­tients with ad­vanced high-grade ep­ithe­lial ovar­i­an can­cer with­out tu­mor BR­CA mu­ta­tions.

In the in­ter­im analy­sis, As­traZeneca said that in the three-arm tri­al, pa­tients treat­ed with the Lyn­parza-Imfinzi com­bo as well as chemo and be­va­cizum­ab (Avastin) demon­strat­ed a sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment in the pri­ma­ry end­point of pro­gres­sion-free sur­vival ver­sus the con­trol group, which was on­ly treat­ed with chemo and be­va­cizum­ab (con­trol arm), but didn’t re­lease spe­cif­ic da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.